Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 91

1.

68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.

Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, Giesel F, Haberkorn U, Hope TA, Kopka K, Krause BJ, Mottaghy FM, Schöder H, Sunderland J, Wan S, Wester HJ, Fanti S, Herrmann K.

Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024. doi: 10.1007/s00259-017-3670-z.

PMID:
28283702
2.

68Ga-DOTATOC Imaging of Neuroendocrine Tumors: A Systematic Review and Meta-Analysis.

Graham MM, Gu X, Ginader T, Breheny P, Sunderland J.

J Nucl Med. 2017 Mar 9. pii: jnumed.117.191197. doi: 10.2967/jnumed.117.191197. [Epub ahead of print]

PMID:
28280220
3.

Multi-site quality and variability analysis of 3D FDG PET segmentations based on phantom and clinical image data.

Beichel RR, Smith BJ, Bauer C, Ulrich EJ, Ahmadvand P, Budzevich MM, Gillies RJ, Goldgof D, Grkovski M, Hamarneh G, Huang Q, Kinahan PE, Laymon CM, Mountz JM, Muzi JP, Muzi M, Nehmeh S, Oborski MJ, Tan Y, Zhao B, Sunderland JJ, Buatti JM.

Med Phys. 2017 Feb;44(2):479-496. doi: 10.1002/mp.12041.

PMID:
28205306
4.

Localization of Unknown Primary Site with 68Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor.

Menda Y, O'Dorisio TM, Howe J, Schultz MK, Dillon J, Dick D, Watkins LG, Ginader T, Bushnell DL, Sunderland J, Zamba GK, Graham MM, O'Dorisio MS.

J Nucl Med. 2017 Feb 2. pii: jnumed.116.180984. doi: 10.2967/jnumed.116.180984. [Epub ahead of print]

PMID:
28153957
5.

Transgenic mouse model of IgM+ lymphoproliferative disease mimicking Waldenström macroglobulinemia.

Tompkins VS, Sompallae R, Rosean TR, Walsh S, Acevedo M, Kovalchuk AL, Han SS, Jing X, Holman C, Rehg JE, Herms S, Sunderland JS, Morse HC, Janz S.

Blood Cancer J. 2016 Nov 4;6(11):e488. doi: 10.1038/bcj.2016.95.

6.

Brown Adipose Reporting Criteria in Imaging STudies (BARCIST 1.0): Recommendations for Standardized FDG-PET/CT Experiments in Humans.

Chen KY, Cypess AM, Laughlin MR, Haft CR, Hu HH, Bredella MA, Enerbäck S, Kinahan PE, Lichtenbelt Wv, Lin FI, Sunderland JJ, Virtanen KA, Wahl RL.

Cell Metab. 2016 Aug 9;24(2):210-22. doi: 10.1016/j.cmet.2016.07.014. Review.

PMID:
27508870
7.

Using [(18)F]Fluorothymidine Imaged With Positron Emission Tomography to Quantify and Reduce Hematologic Toxicity Due to Chemoradiation Therapy for Pelvic Cancer Patients.

McGuire SM, Bhatia SK, Sun W, Jacobson GM, Menda Y, Ponto LL, Smith BJ, Gross BA, Bayouth JE, Sunderland JJ, Graham MM, Buatti JM.

Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):228-39. doi: 10.1016/j.ijrobp.2016.04.009. Epub 2016 Apr 19.

PMID:
27319286
8.

Semiautomated segmentation of head and neck cancers in 18F-FDG PET scans: A just-enough-interaction approach.

Beichel RR, Van Tol M, Ulrich EJ, Bauer C, Chang T, Plichta KA, Smith BJ, Sunderland JJ, Graham MM, Sonka M, Buatti JM.

Med Phys. 2016 Jun;43(6):2948. doi: 10.1118/1.4948679.

9.

Do Cochrane summaries help student midwives understand the findings of Cochrane systematic reviews: the BRIEF randomised trial.

Alderdice F, McNeill J, Lasserson T, Beller E, Carroll M, Hundley V, Sunderland J, Devane D, Noyes J, Key S, Norris S, Wyn-Davies J, Clarke M.

Syst Rev. 2016 Mar 1;5:40. doi: 10.1186/s13643-016-0214-8.

10.

An algorithm for automated ROI definition in water or epoxy-filled NEMA NU-2 image quality phantoms.

Pierce Ii LA, Byrd DW, Elston BF, Karp JS, Sunderland JJ, Kinahan PE.

J Appl Clin Med Phys. 2016 Jan 8;17(1):5842.

11.

Fluorine-18-Labeled Thymidine Positron Emission Tomography (FLT-PET) as an Index of Cell Proliferation after Pharmacological Ascorbate-Based Therapy.

Cieslak JA, Sibenaller ZA, Walsh SA, Ponto LL, Du J, Sunderland JJ, Cullen JJ.

Radiat Res. 2016 Jan;185(1):31-8. doi: 10.1667/RR14203.1. Epub 2015 Dec 31.

12.

An algorithm for automated ROI definition in water or epoxy-filled NEMA NU-2 image quality phantoms.

Pierce LA 2nd, Byrd DW, Elston BF, Karp JS, Sunderland JJ, Kinahan PE.

J Appl Clin Med Phys. 2016 Jan;17(1):440-456. doi: 10.1120/jacmp.v17i1.5842.

PMID:
28297491
13.

Diagnostic Reference Levels of CT Radiation Dose in Whole-Body PET/CT.

Jallow N, Christian P, Sunderland J, Graham M, Hoffman JM, Nye JA.

J Nucl Med. 2016 Feb;57(2):238-41. doi: 10.2967/jnumed.115.160465. Epub 2015 Nov 12.

14.

Preliminary Investigation of Cerebral Blood Flow and Amyloid Burden in Veterans With and Without Combat-Related Traumatic Brain Injury.

Ponto LL, Brashers-Krug TM, Pierson RK, Menda Y, Acion L, Watkins GL, Sunderland JJ, Koeppel JA, Jorge RE.

J Neuropsychiatry Clin Neurosci. 2016 Spring;28(2):89-96. doi: 10.1176/appi.neuropsych.15050106. Epub 2015 Nov 9.

PMID:
26548655
15.

Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials.

Graham MM, Wahl RL, Hoffman JM, Yap JT, Sunderland JJ, Boellaard R, Perlman ES, Kinahan PE, Christian PE, Hoekstra OS, Dorfman GS.

J Nucl Med. 2015 Jun;56(6):955-61. doi: 10.2967/jnumed.115.158402. Epub 2015 Apr 16.

16.

PET/CT imaging reveals unrivaled placental avidity for glucose compared to other tissues.

Sawatzke AB, Norris AW, Spyropoulos F, Walsh SA, Acevedo MR, Hu S, Yao J, Wang C, Sunderland JJ, Boles Ponto LL.

Placenta. 2015 Feb;36(2):115-20. doi: 10.1016/j.placenta.2014.12.009. Epub 2014 Dec 23.

17.
18.

Dependency of cardiac rubidium-82 imaging quantitative measures on age, gender, vascular territory, and software in a cardiovascular normal population.

Sunderland JJ, Pan XB, Declerck J, Menda Y.

J Nucl Cardiol. 2015 Feb;22(1):72-84. doi: 10.1007/s12350-014-9920-6. Epub 2014 Oct 8.

PMID:
25294436
19.

Locally targeted delivery of a micron-size radiation therapy source using temperature-sensitive hydrogel.

Kim Y, Seol DR, Mohapatra S, Sunderland JJ, Schultz MK, Domann FE, Lim TH.

Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1142-7. doi: 10.1016/j.ijrobp.2013.12.025. Epub 2014 Feb 1.

20.

(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.

Duncan K, Rosean TR, Tompkins VS, Olivier A, Sompallae R, Zhan F, Tricot G, Acevedo MR, Ponto LL, Walsh SA, Tygrett LT, Berger AJ, Waldschmidt T, Morse HC 3rd, Sunderland JJ, Janz S.

Blood Cancer J. 2013 Nov 29;3:e165. doi: 10.1038/bcj.2013.61.

Supplemental Content

Loading ...
Support Center